The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
The inhibition of HIV-1’s replicative machinery remains a cornerstone in the battle against AIDS. Central to this approach are inhibitors targeting reverse transcriptase (RT) and integrase. Reverse ...
The crystal structure of a human endogenous reverse transcriptase has similarities to HIV reverse transcriptase, a well-known tractable drug target, which will help design drugs to treat cancer and ...
† Drugs combined with NRTIs or NRTIs/NNRTIs are not listed. NNRTIs: Non-nucleoside reverse-transcriptase inhibitors; NRTIs: Nucleos(t)ide analog reverse-transcriptase inhibitors. Drug-resistance amino ...
Tenofovir was approved by the Food and Drug Administration (FDA) in October 2001 through an accelerated approval process; it is the first nucleotide analogue reverse-transcriptase inhibitor marketed ...
One of the hallmarks of many DNA polymerases is that they proofread as they copy DNA, ensuring high-fidelity duplicates of an organism’s genome. This error-checking ability is missing from enzymes ...
After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback